The Effectiveness of Tirzepatide (GIP/GLP-1 Receptor co-Agonist) vs GLP-1 Receptor Agonists on Lowering A1C in Adults with Type 2 Diabetes Mellitus

Authors

Madison LaPlante, Thomas Jefferson UniversityFollow

Files

Description

Introduction

In the United States, 34.2 million people are currently diagnosed with diabetes mellitus, which accounts for 10.5% of the total population.¹ Type 2 diabetes mellitus (T2DM) holds 94.2% of all diabetes diagnoses. The American Association of Diabetes estimates approximately $327 billion annually and is broken up as follows:¹

Publication Date

8-17-2023

Keywords

tirzepatide, GLP-1 receptor agonists, type-2 diabetes

Disciplines

Medicine and Health Sciences | Nephrology

Comments

Capstone presentations were completed in partial fulfillment of the Master of Science degree in Physician Assistant Studies at Thomas Jefferson University.

Document Type

Presentation

Recommended Citation

LaPlante, Madison, "The Effectiveness of Tirzepatide (GIP/GLP-1 Receptor co-Agonist) vs GLP-1 Receptor Agonists on Lowering A1C in Adults with Type 2 Diabetes Mellitus" (2023). Master of Science in Physician Assistant Studies Capstone Presentations (Center City). 16.
https://jdc.jefferson.edu/mspas_capstones/16